TY  - JOUR
U1  - Wissenschaftlicher Artikel
A1  - Pink, Daniel
A1  - Richter, Stephan
A1  - Gerdes, Sebastian
A1  - Andreou, Dimosthenis
A1  - Tunn, Per-Ulf
A1  - Busemann, Christoph
A1  - Ehninger, Gerhard
A1  - Reichardt, Peter
A1  - Schuler, Markus K.
T1  - Gemcitabine and Docetaxel for Epithelioid Sarcoma: Results from a Retrospective, Multi-Institutional Analysis
JF  - Oncology
N2  - Objective: Epithelioid sarcoma (ES) presents unique clinical features in comparison to other sarcoma subtypes. Data regarding the benefits of chemotherapy are very limited. Combination regimens using gemcitabine and docetaxel (Gem/Doce) have proven to be effective, especially in uterine and nonuterine leiomyosarcoma. Yet, there is no available data on the efficacy of Gem/Doce in ES. Methods: A retrospective analysis of the three participating institutions was performed. Twenty-eight patients with an ES diagnosis presented at one of the participating institutions between 1989 and 2012. Of this group, 17 patients received chemotherapy. Results: Patients' median overall survival (OS) after the beginning of palliative chemotherapy was 21 months, and the 1-year OS was 87%. Twelve patients received Gem/Doce with a clinical benefit rate of 83%. The median progression-free survival (PFS) was 8 months for all patients receiving Gem/Doce. The best response was complete remission in 1 patient and partial remission in 6 patients. All 6 patients receiving Gem/Doce as a first-line treatment showed measurable responses with a median PFS of 9 months. Conclusions: In this retrospective study, Gem/Doce was an effective chemotherapeutic regimen for ES. Prospective studies are needed to better assess the effects of this combination drug therapy.
KW  - -
KW  - Sarcoma
KW  - Epithelioid sarcoma
KW  - Gemcitabine
KW  - Docetaxel
KW  - Chemotherapy
KW  - Combination chemotherapy
KW  - Soft tissue sarcoma
KW  - Palliative chemotherapy
Y1  - 2014
UN  - https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-31068
UR  - www.karger.com/ocl
SN  - 0030-2414
SS  - 0030-2414
SN  - 1423-0232
SS  - 1423-0232
U6  - https://doi.org/10.1159/000362602
DO  - https://doi.org/10.1159/000362602
PM  - 25011671
VL  - 87
IS  - 2
SP  - 95
EP  - 103
PB  - S. Karger AG
CY  - Basel, Switzerland
ER  -